As demand for Ozempic & WeGovy continues to rise, what are the effects on the food sector? Does the sector anticipate that Europe will also experience the same hype around GLP-1 drugs? How are companies working to understand how to support the needs of their consumers using GLP-1 solutions, both during usage and afterward? How are product ranges and reformulation evolving to address these needs? What range of solutions are being developed to provide natural alternatives to GLP-1 drugs, and help consumers manage appetite management and glucose control?